At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Hydroxychloroquine/Atorvastatindrug
Likely dose
Hydroxychloroquine/Atorvastatin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Hydroxychloroquine/Atorvastatin in the Treatment of OA of the Knee
In Brief
A Phase 2 clinical trial evaluating Hydroxychloroquine/Atorvastatin for Osteoarthritis of the Knee. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The purpose of this study of a combination therapy of hydroxychloroquine and atorvastatin is to learn about the effects in inflammation and pain in patients with Osteoarthritis of the knee. These medications are FDA approved and commercially available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedJul 2012
Primary CompletionApr 2016
Study CompletionOct 2016
TodayJul 2026
First PostedJul 20, 2012
Enrollment StartMay 1, 2012
Primary CompletionApr 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.0 years ago
Interventions
Hydroxychloroquine/Atorvastatindrug
Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day